$INGN
Inogen Inc Stock $ingn

$ingn Overview Financials Valuation SEC Filings Company Website

2017 Form 10-K Financial Statement

#000156459018003518 Filed on February 27, 2018

Income Statement

Concept	2017	2016 Q4	2016 Q2
Revenue	$249.4M	$50.90M	$54.57M
YoY Change	48.32%	25.85%	23.93%
Cost Of Revenue	$128.2M	$26.20M	$28.35M
YoY Change	21.52%	28.43%	22.17%
Gross Profit	$121.2M	$24.70M	$26.22M
YoY Change	24.59%	23.27%	25.9%
Gross Profit Margin	48.6%	48.53%	48.04%
Selling, General & Admin	$88.33M	$17.30M	$16.82M
YoY Change	27.41%	13.07%	15.96%
% of Gross Profit	72.86%	70.04%	64.15%
Research & Development	$5.313M	$1.200M	$1.379M
YoY Change	3.91%	0.0%	41.44%
% of Gross Profit	4.38%	4.86%	5.26%
Depreciation & Amortization	$12.30M	$3.270M	$3.420M
YoY Change	-9.26%	-7.63%	-1.44%
% of Gross Profit	10.15%	13.24%	13.05%
Operating Expenses	$93.65M	$18.50M	$18.20M
YoY Change	25.79%	11.45%	17.57%
Operating Profit	$27.59M	$6.200M	$8.019M
YoY Change	20.67%	80.34%	50.03%
Interest Expense	$800.0K	$100.0K	$2.000K
YoY Change	13233.33%		-66.67%
% of Operating Profit	2.9%	1.61%	0.02%
Other Income/Expense, Net	$2.066M	-$400.0K	$23.00K
YoY Change	-1586.33%	100.0%	-174.19%
Pretax Income	$29.66M	$5.834M	$8.042M
YoY Change	30.5%	75.88%	51.34%
Income Tax	$8.654M	$574.0K	$550.0K
% Of Pretax Income	29.18%	9.84%	6.84%
Net Earnings	$21.00M	$9.600M	$7.492M
YoY Change	2.35%	148.83%	116.59%
Net Earnings / Revenue	8.42%	18.86%	13.73%
Basic Earnings Per Share	$1.02		$0.38
Diluted Earnings Per Share	$0.96	$0.25	$0.36
COMMON SHARES
Basic Shares Outstanding	20.68M	20.31M	19.97M
Diluted Shares Outstanding	21.90M	21.36M	21.00M

Balance Sheet

Concept	2017	2016 Q4	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$173.9M	$113.9M	$98.10M
YoY Change	52.68%	37.38%	48.41%
Cash & Equivalents	$143.0M	$92.85M	$84.50M
Short-Term Investments	$31.00M	$21.03M	$13.60M
Other Short-Term Assets	$3.000M	$2.100M	$2.900M
YoY Change	42.86%	61.54%	-59.15%
Inventory	$18.80M	$14.34M	$12.51M
Prepaid Expenses
Receivables	$31.40M	$30.83M	$27.84M
Other Receivables	$1.400M	$500.0K	$1.300M
Total Short-Term Assets	$228.5M	$161.5M	$142.6M
YoY Change	41.49%	40.63%	30.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$20.10M	$25.20M	$28.44M
YoY Change	-20.24%	-17.86%	-11.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$19.40M	$410.0K	$97.00K
YoY Change	-28.41%	322.68%	-99.37%
Total Long-Term Assets	$46.60M	$52.55M	$54.96M
YoY Change	-11.24%	13.08%	14.97%
TOTAL ASSETS
Total Short-Term Assets	$228.5M	$161.5M	$142.6M
Total Long-Term Assets	$46.60M	$52.55M	$54.96M
Total Assets	$275.1M	$214.0M	$197.5M
YoY Change	28.55%	32.69%	25.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.500M	$5.738M	$11.06M
YoY Change	66.67%	-22.96%	-35.71%
Accrued Expenses	$10.70M	$8.900M	$6.400M
YoY Change	20.22%	67.92%	48.84%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$159.0K
YoY Change		-100.0%	-47.0%
Total Short-Term Liabilities	$33.90M	$22.85M	$27.98M
YoY Change	48.68%	3.78%	11.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$13.80M	$282.0K	$340.0K
YoY Change	51.65%	-16.32%	-91.5%
Total Long-Term Liabilities	$13.80M	$282.0K	$340.0K
YoY Change	51.65%	-16.32%	-91.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.90M	$22.85M	$27.98M
Total Long-Term Liabilities	$13.80M	$282.0K	$340.0K
Total Liabilities	$48.00M	$31.96M	$35.28M
YoY Change	50.0%	17.09%	20.42%
SHAREHOLDERS EQUITY
Retained Earnings		-$12.36M	-$22.87M
YoY Change		-72.59%
Common Stock		$194.5M	$185.1M
YoY Change		8.55%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$227.0M	$182.1M	$162.2M
YoY Change
Total Liabilities & Shareholders Equity	$275.1M	$214.0M	$182.8M
YoY Change	28.55%	32.69%	16.28%

Cashflow Statement

Concept	2017	2016 Q4	2016 Q2
OPERATING ACTIVITIES
Net Income	$21.00M	$9.600M	$7.492M
YoY Change	2.35%	148.83%	116.59%
Depreciation, Depletion And Amortization	$12.30M	$3.270M	$3.420M
YoY Change	-9.26%	-7.63%	-1.44%
Cash From Operating Activities	$60.49M	$5.180M	$12.02M
YoY Change	94.93%	-58.76%	56.31%
INVESTING ACTIVITIES
Capital Expenditures	$2.914M	-$230.0K	-$520.0K
YoY Change	69.62%	-42.5%	-28.77%
Acquisitions	$4.494M
YoY Change
Other Investing Activities	-$18.20M	-$320.0K	-$1.120M
YoY Change	80.2%	357.14%	-93.51%
Cash From Investing Activities	-$24.43M	-$550.0K	-$1.630M
YoY Change	104.83%	14.58%	-90.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	14.00M	2.290M	1.820M
YoY Change	81.54%	-308.18%	82.0%
NET CHANGE
Cash From Operating Activities	60.49M	5.180M	12.02M
Cash From Investing Activities	-24.43M	-550.0K	-1.630M
Cash From Financing Activities	14.00M	2.290M	1.820M
Net Change In Cash	50.10M	6.920M	12.21M
YoY Change	86.8%	-36.98%	-231.57%
FREE CASH FLOW
Cash From Operating Activities	$60.49M	$5.180M	$12.02M
Capital Expenditures	$2.914M	-$230.0K	-$520.0K
Free Cash Flow	$57.58M	$5.410M	$12.54M
YoY Change	96.41%	-58.26%	48.93%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	30991000
CY2017Q4	us-gaap	Goodwill Goodwill	2363000
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	9402000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5113000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-329000
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	21033000
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30828000
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	765000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1301000
CY2017	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-567000
CY2017	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-121000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2206000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	21002000
CY2016	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	55000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	20519000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	14727000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	363000
CY2017	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-446000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	134018000
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	410000
CY2016Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	26654000
CY2016Q4	us-gaap	Assets Assets	214049000
CY2016Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	12795000
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6123000
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	345000
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	348000
CY2016Q4	us-gaap	Inventory Net InventoryNet	14343000
CY2016Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	398000
CY2016Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	433000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	241000
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3142000
CY2017	us-gaap	Gross Profit GrossProfit	121237000
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	128201000
CY2017	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	115329000
CY2016	ingn	Gross Profit Sales Revenue GrossProfitSalesRevenue	83016000
CY2015	us-gaap	Operating Expenses OperatingExpenses	61207000
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	31369000
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	50758000
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25658000
CY2017	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	5908000
CY2016	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	14294000
CY2015	ingn	Gross Profit Rental Revenue GrossProfitRentalRevenue	24186000
CY2016	us-gaap	Gross Profit GrossProfit	97310000
CY2015	us-gaap	Gross Profit GrossProfit	76258000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5313000
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4180000
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37540000
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	37576000
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31793000
CY2017	us-gaap	Operating Expenses OperatingExpenses	93647000
CY2016	us-gaap	Operating Expenses OperatingExpenses	74446000
CY2015	us-gaap	Net Income Loss NetIncomeLoss	11585000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	27590000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	22864000
CY2016	us-gaap	Interest Expense InterestExpense	6000
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	196000
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	102000
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-404000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6974000
CY2015	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-37000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	21309000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	20521000
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11548000
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.02
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2066000
CY2015	us-gaap	Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax	-14000
CY2016	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax	-6000
CY2016	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	61000
CY2015	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-14000
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	65000
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-23000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	307000
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2000
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.96
CY2017Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	754000
CY2016Q4	ingn	Rental Equipment Allowance RentalEquipmentAllowance	725000
CY2016	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.97
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.56
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20683807
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20067152
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19398991
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21897988
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21095867
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20708170
CY2017	us-gaap	Cost Of Services Depreciation CostOfServicesDepreciation	9835000
CY2016	us-gaap	Cost Of Services Depreciation CostOfServicesDepreciation	11429000
CY2015	us-gaap	Cost Of Services Depreciation CostOfServicesDepreciation	11965000
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	118150000
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3640000
CY2015	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	701000
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1615000
CY2015	ingn	Stock Issued During Period Value Stock Warrants Exercised StockIssuedDuringPeriodValueStockWarrantsExercised	5000
CY2015	us-gaap	Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet	-1641000
CY2016	ingn	Cumulative Effect Of Change In Accounting Principle CumulativeEffectOfChangeInAccountingPrinciple	12226000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7294000
CY2016	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1055000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	12625000
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	14012000
CY2016	ingn	Gain Loss On Write Off Of Rental Units And Other Fixed Assets GainLossOnWriteOffOfRentalUnitsAndOtherFixedAssets	-1202000
CY2015	ingn	Gain Loss On Write Off Of Rental Units And Other Fixed Assets GainLossOnWriteOffOfRentalUnitsAndOtherFixedAssets	-1214000
CY2017	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	64000
CY2016	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	272000
CY2017	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	13773000
CY2016	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	11082000
CY2015	ingn	Provision For Sales Returns And Doubtful Accounts ProvisionForSalesReturnsAndDoubtfulAccounts	7598000
CY2017	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	5057000
CY2016	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	10777000
CY2015	ingn	Health Care Organization Patient Service Revenue Adjustments HealthCareOrganizationPatientServiceRevenueAdjustments	8543000
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	340000
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	133000
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	89000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	9640000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	7294000
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	3640000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	7947000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	1036000
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4760000
CY2015	ingn	Excess Tax Benefit Expense From Share Based Compensation Operating Activities ExcessTaxBenefitExpenseFromShareBasedCompensationOperatingActivities	-1641000
CY2017	ingn	Percentage Of Non Us Revenue Invoiced In Euros PercentageOfNonUSRevenueInvoicedInEuros	0.735
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-118000
CY2017	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	875000
CY2016	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-1725000
CY2015	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	1670000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	819000
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	789000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	507000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	18263000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	32738000
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	16699000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5894000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7458000
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2570000
CY2017	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-37000
CY2016	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1000
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-86000
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	722000
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	86000
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	38161000
CY2015	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	36626000
CY2016	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	28843000
CY2015	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	19810000
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	3316000
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	113000
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-252000
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7438000
CY2015	us-gaap	Product Warranty Accrual Period Increase Decrease ProductWarrantyAccrualPeriodIncreaseDecrease	858000
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2759000
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2030000
CY2017	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	225000
CY2016	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-11000
CY2015	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	11000
CY2017	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	447000
CY2016	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-55000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	60494000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	31034000
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	45000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2914000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1718000
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2208000
CY2017	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	3997000
CY2016	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	6185000
CY2015	ingn	Payments To Produce And Purchase Rental Equipment PaymentsToProduceAndPurchaseRentalEquipment	10236000
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	183000
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	388000
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	4494000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-24430000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-11927000
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-29305000
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	5000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12625000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6974000
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1615000
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1379000
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1055000
CY2015	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	701000
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	315000
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	299000
CY2015	ingn	Excess Tax Benefit Expense From Share Based Compensation Financing Activities ExcessTaxBenefitExpenseFromShareBasedCompensationFinancingActivities	-1641000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14004000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	7714000
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	381000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	34000
CY2016	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	-76000
CY2015	us-gaap	Effect Of Exchange Rate On Cash Continuing Operations EffectOfExchangeRateOnCashContinuingOperations	33000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	101000
CY2016Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	39277000
CY2017Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	490000
CY2017Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	1470000
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	48533000
CY2017Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	93430000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13457000
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	50102000
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	26745000
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9270000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66106000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	56836000
CY2016	us-gaap	Interest Paid InterestPaid	10000
CY2015	us-gaap	Interest Paid InterestPaid	26000
CY2017	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1267000
CY2016	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-447000
CY2015	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	19000
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	70000
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which the Company calls the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One<sup style="font-size:85%; vertical-align:top">®</sup> systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 2.8, 4.8 or 7.0 pounds with a single battery.<font style="font-size:12pt;"> </font>The Company’s Inogen One G4<sup style="font-size:85%; vertical-align:top">®</sup>,<sup style="font-size:85%; vertical-align:top"> </sup>Inogen One G3<sup style="font-size:85%; vertical-align:top">®</sup> and Inogen One G2<sup style="font-size:85%; vertical-align:top">®</sup> have up to 2.6, 4.7 and 5.0 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available.<font style="font-size:12pt;"> </font> The Company’s Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portable oxygen concentrators represented the fastest-growing segment of the Medicare oxygen therapy market between 2012 and 2016. The Company estimates based on 2016 Medicare data that the number of patients using portable oxygen concentrators represented approximately 9.1% of the total addressable oxygen market in the United States, although the Medicare data does not account for private insurance and cash-pay patients in the market. Based on 2016 industry data, the Company believes it was the leading worldwide manufacturer of portable oxygen concentrators. The Company believes it is the only manufacturer of portable oxygen concentrators that employs a direct-to-consumer strategy in the United States, meaning the Company markets its products to patients, processes their physician paperwork, provides clinical support as needed and bills Medicare or insurance on their behalf. To pursue a direct-to-consumer strategy, the Company’s manufacturing competitors would need to meet national accreditation and state-by-state licensing requirements and secure Medicare billing privileges including Medicare competitive bidding contracts, as well as compete with the home medical equipment providers who many of the Company’s manufacturing competitors sell to across their entire homecare business. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since adopting the Company’s direct-to-consumer strategy in 2009 following its acquisition of Comfort Life Medical Supply, LLC, which had an active Medicare billing number but few other assets and limited business activities, the Company has directly sold or rented more than 362,000 of its Inogen oxygen concentrators as of December 31, 2017.  </p></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Accounting estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, inventory and rental asset valuations and write-downs, accounts receivable allowances for bad debts, returns and adjustments, warranty expense, stock compensation expense, depreciation and amortization, income tax provision and uncertain tax positions, fair value of financial instruments, and fair value of acquired intangible assets and goodwill.  Actual results could differ from these estimates. </p></div>
CY2017	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<div> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Derivative instruments and hedging activities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company transacts business in foreign currencies and has international sales and expenses denominated in foreign currencies, subjecting the Company to foreign currency risk. The Company has entered into foreign currency forward contracts, generally with maturities of twelve months or less, to reduce the volatility of cash flows primarily related to forecasted revenue denominated in certain foreign currencies. These contracts allow the Company to sell Euros in exchange for U.S. dollars at specified contract rates. Forward contracts are used to hedge forecasted sales over specific months. Changes in the fair value of these forward contracts designed as cash flow hedges are recorded as a component of accumulated other comprehensive income (loss) income within stockholders’ equity and are recognized in the Consolidated Statements of Comprehensive Income during the period which approximates the time the corresponding sales occur. The Company may also enter into foreign exchange contracts that are not designated as hedging instruments for financial accounting purposes. These contracts are generally entered into to offset the gains and losses on certain asset and liability balances until the expected time of repayment. Accordingly, any gains or losses resulting from changes in the fair value of the non-designated contracts are reported in other expense, net in the Consolidated Statements of Comprehensive Income. The gains and losses on these contracts generally offset the gains and losses associated with the underlying foreign currency-denominated balances, which are also reported in other income (expense), net.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records the assets or liabilities associated with derivative instruments and hedging activities at fair value based on Level 2 inputs in other current assets or other current liabilities, respectively, in the consolidated balance sheet. The Company had a payable of $66 and a receivable of $15 as of December 31, 2017 and 2016, respectively. The Company classifies the foreign currency derivative instruments within Level 2 in the fair value hierarchy as the valuation inputs are based on quoted prices and market observable data of whether it is designated and qualifies for hedge accounting.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company documents the hedging relationship and its risk management objective and strategy for undertaking the hedge, the hedging instrument, the hedged transaction, the nature of the risk being hedged, how the hedging instrument’s effectiveness in offsetting the hedged risk will be assessed prospectively and retrospectively, and a description of the method used to measure ineffectiveness. The Company assesses hedge effectiveness and ineffectiveness at a minimum quarterly but may assess it monthly. For derivative instruments that are designed and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivative is reported in other comprehensive income (loss) and reclassified into earnings in the same periods during which the hedged transaction affects earnings. Gains and losses on the derivative representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in current period earnings.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will discontinue hedge accounting prospectively when it determines that the derivative is no longer effective in offsetting cash flows attributable to the hedge risk. The cash flow hedge is de-designated because a forecasted transaction is not probable of occurring, or management determines to remove the designation of the cash flow hedge.  In all situations in which hedge accounting is discontinued and the derivative remains outstanding, the Company continues to carry the derivative at its fair value on the balance sheet and recognizes any subsequent changes in the fair value in earnings. When it is probable that a forecasted transaction will not occur, the Company will discontinue hedge accounting and recognize immediately in earnings gains and losses that were accumulated in other comprehensive income (loss) related to the hedging relationship.</p></div>
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5738000
CY2017Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	7252000
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4290000
CY2017Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	2381000
CY2016Q4	ingn	Accrued Purchasing Card Liability AccruedPurchasingCardLiability	1760000
CY2017Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	479000
CY2016Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	281000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	973000
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	726000
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of credit risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents to date. The Company has also entered into hedging relationships with a single counterparty to offset the forecasted Euro-based revenues. The credit risk has been reduced due to a net settlement arrangement whereby the Company is allowed to net settle transactions with a single net amount payable by one party to the other.</p></div>
CY2017	ingn	Patients Using Portable Oxygen Concentrators PatientsUsingPortableOxygenConcentrators	0.091
CY2017Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	6171000
CY2016Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	3480000
CY2017	us-gaap	Extended Product Warranty Description ExtendedProductWarrantyDescription	The second deliverable is the lifetime warranty that provides for a functional oxygen concentrator for the remaining lifetime of the patient
CY2017	ingn	Number Of Deliverables When Lifetime Warranty Is Sold NumberOfDeliverablesWhenLifetimeWarrantyIsSold	2
CY2017	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The first deliverable is the oxygen concentrator equipment which comes with a standard warranty of three years and the additional service component is broken out from the product sales and deferred and recognized in years four and five to correspond with the service period.
CY2016Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	585000
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3266000
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	8532000
CY2017	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.041
CY2016	ingn	Doubtful Accounts Percentage DoubtfulAccountsPercentage	0.047
CY2017	ingn	Rental Revenue Adjustments Percentage RentalRevenueAdjustmentsPercentage	0.027
CY2016	ingn	Rental Revenue Adjustments Percentage RentalRevenueAdjustmentsPercentage	0.154
CY2017	ingn	Sales Returns Percentage SalesReturnsPercentage	0.026
CY2016	ingn	Sales Returns Percentage SalesReturnsPercentage	0.015
CY2017	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.094
CY2016	ingn	Allowance For Doubtful Accounts Receivable Current Percentage AllowanceForDoubtfulAccountsReceivableCurrentPercentage	0.216
CY2017	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1055000
CY2016	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1454000
CY2015	ingn	Transfer Of Inventory To Rental Equipment TransferOfInventoryToRentalEquipment	1449000
CY2017Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	16324000
CY2017	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	1.000
CY2016	us-gaap	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable	1.000
CY2017	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2016	ingn	Health Care Organization Allowance For Doubtful Accounts Percentage Of Accounts Receivable Net HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivableNet	1.000
CY2016Q4	us-gaap	Inventory Work In Process And Raw Materials InventoryWorkInProcessAndRawMaterials	12382000
CY2017Q4	ingn	Doubtful Accounts DoubtfulAccounts	1415000
CY2016Q4	ingn	Doubtful Accounts DoubtfulAccounts	1869000
CY2017Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	947000
CY2016Q4	ingn	Rental Revenue Adjustments RentalRevenueAdjustments	6078000
CY2017Q4	ingn	Allowances For Sales Returns AllowancesForSalesReturns	904000
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2917000
CY2016Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2152000
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	399000
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	191000
CY2017Q4	us-gaap	Property Plant And Equipment Salvage Value PropertyPlantAndEquipmentSalvageValue	0
CY2017	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2385000
CY2016	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2464000
CY2015	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	2520000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	11795000
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	13926000
CY2017	us-gaap	Revenue Recognition Multiple Deliverable Arrangements Determination Of Selling Price Method RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceMethod	the Company estimates that 60% of its patients will succumb to their disease within three years of initial diagnosis. Given the approximate mortality rate of 20% per year, the Company estimates on average its patients will succumb to their disease within five years of initial diagnosis.
CY2017Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2016Q4	ingn	Deferred Capped Rental Revenue DeferredCappedRentalRevenue	0
CY2017	us-gaap	Revenue Recognition New Accounting Pronouncement Timing RevenueRecognitionNewAccountingPronouncementTiming	30-day period
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue	30991000
CY2017Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	46237000
CY2016Q4	us-gaap	Certificates Of Deposit At Carrying Value CertificatesOfDepositAtCarryingValue	5041000
CY2017Q4	ingn	Corporate Bonds At Carrying Value CorporateBondsAtCarryingValue	2796000
CY2016Q4	us-gaap	Unbilled Receivables Current UnbilledReceivablesCurrent	7484000
CY2017	ingn	Increase Decrease In Provisions For Bad Debt And Revenue Adjustments IncreaseDecreaseInProvisionsForBadDebtAndRevenueAdjustments	3442000
CY2016	ingn	Increase Decrease In Provisions For Bad Debt And Revenue Adjustments IncreaseDecreaseInProvisionsForBadDebtAndRevenueAdjustments	3589000
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	34710000
CY2016Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	39360000
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2016	us-gaap	Advertising Expense AdvertisingExpense	6215000
CY2015	us-gaap	Advertising Expense AdvertisingExpense	4686000
CY2016	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	10579
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2017	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	2154000
CY2017Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3086000
CY2016Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3643000
CY2017Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	2453000
CY2016Q4	ingn	Accrued Wages And Other Payroll Related Items Current AccruedWagesAndOtherPayrollRelatedItemsCurrent	1360000
CY2017Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1338000
CY2016Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1120000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	786000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	545000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9541000
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	209000
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6338000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1345000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1621000
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1104000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1193000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1138000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1055000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	29121000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	22725000
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	14727000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	535000
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	245000
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	206000
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-38000
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3639000
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	705000
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-71000
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1947000
CY2015	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	4344000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	968000
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1164000
CY2016	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	979000
CY2015	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	3180000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	10378000
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16505000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	3301000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	8690000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2598000
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2378000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	21946000
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	33772000
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	767000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21946000
CY2016Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	33005000
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	3658000
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	6351000
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	18288000
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	26654000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.3400
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0088
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0200
CY2017	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.3040
CY2016	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	-0.2374
CY2015	ingn	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Expense Benefit EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationExpenseBenefit	0.0065
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.0259
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0143
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0297
CY2017	ingn	Effective Income Tax Rate Reconciliation Net Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration	0.0276
CY2016	ingn	Effective Income Tax Rate Reconciliation Net Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration	0.0451
CY2015	ingn	Effective Income Tax Rate Reconciliation Net Operating Loss Expiration EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration	0.0117
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Prior Year Income Taxes EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes	-0.0311
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.2555
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0092
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0007
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.0250
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2918
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0971
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.2133
CY2017Q4	ingn	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Provisional Net Charge TaxCutsAndJobsActOf2017ChangeInTaxRateProvisionalNetCharge	7578000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1062000
CY2016Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	934000
CY2015Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	773000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	934000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	773000
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	577000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	128000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	161000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	176000
CY2015	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	20000
CY2017	ingn	Voting Rights Associated With Each Share Of Common Stock VotingRightsAssociatedWithEachShareOfCommonStock	1
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2016	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2015	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	0
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2261633
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	759301
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	676715
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	48849
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	933707
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2179294
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	683998
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	570079
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	53247
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	515
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2355527
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1023865
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2259811
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	64498
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	520393
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	63173
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	33
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1836426
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1176504
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1792871
CY2016	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceExpired	8.70
CY2017	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceGranted	83.30
CY2017	ingn	Share Based Compensation Arrangement By Share Based Payment Award Per Share Price Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardPerSharePriceExpired	8.70
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.31
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	39.91
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.39
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	16.28
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	19.36
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.16
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	19.15
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	44.70
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12.32
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	28.09
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.70
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	16.61
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	27.95
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	83.30
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	24.16
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	43.74
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	8.70
CY2017Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	9690000
CY2016Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16057000
CY2015Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	12095000
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3640000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0165
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0100
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0095
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0173
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0140
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0177
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.00
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4161
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4395
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.4199
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4215
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4593
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.4487
CY2017	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	8929000
CY2016	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	6408000
CY2015	ingn	Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodFairValue	2428000
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-37000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1522000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1682000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	1298000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	791000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	572000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	873000
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6738000
CY2017Q4	ingn	Related Party Leases Future Minimum Payments Due Current RelatedPartyLeasesFutureMinimumPaymentsDueCurrent	32000
CY2017Q4	ingn	Related Party Leases Future Minimum Payments Due In Two Years RelatedPartyLeasesFutureMinimumPaymentsDueInTwoYears	32000
CY2017Q4	ingn	Related Party Leases Future Minimum Payments Due In Three Years RelatedPartyLeasesFutureMinimumPaymentsDueInThreeYears	11000
CY2017Q4	ingn	Related Party Leases Future Minimum Payments Due RelatedPartyLeasesFutureMinimumPaymentsDue	75000
CY2017Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	578000
CY2017Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	578000
CY2017Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	578000
CY2017Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	456000
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	2190000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due Current OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDueCurrent	2132000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due In Two Years OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDueInTwoYears	2292000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due In Three Years OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDueInThreeYears	1887000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due In Four Years OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDueInFourYears	1247000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due In Five Years OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDueInFiveYears	572000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due Thereafter OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDueThereafter	873000
CY2017Q4	ingn	Operating Leases Related Party Leases And Non Cancelable Contractual Obligations Minimum Payments Due OperatingLeasesRelatedPartyLeasesAndNonCancelableContractualObligationsMinimumPaymentsDue	9003000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1148000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1028000
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	48900000
CY2015Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1973000
CY2014Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	1115000
CY2017	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	5275000
CY2016	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3123000
CY2015	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	1871000
CY2017	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	200000
CY2016	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	118000
CY2015	us-gaap	Product Warranty Accrual Preexisting Increase Decrease ProductWarrantyAccrualPreexistingIncreaseDecrease	510000
CY2017	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	2784000
CY2016	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1734000
CY2015	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	1523000
CY2017Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	3000000
CY2017Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	18
CY2016Q4	ingn	Number Of Contract Designated Hedges NumberOfContractDesignatedHedges	4
CY2017Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	3
CY2016Q4	ingn	Number Of Contract Non Designated Hedges NumberOfContractNonDesignatedHedges	2
CY2017Q1	us-gaap	Revenues Revenues	52500000
CY2017Q2	us-gaap	Revenues Revenues	64121000
CY2017Q3	us-gaap	Revenues Revenues	69030000
CY2017Q4	us-gaap	Revenues Revenues	63787000
CY2017Q1	us-gaap	Gross Profit GrossProfit	25744000
CY2017Q2	us-gaap	Gross Profit GrossProfit	31567000
CY2017Q3	us-gaap	Gross Profit GrossProfit	33170000
CY2017Q4	us-gaap	Gross Profit GrossProfit	30756000
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5879000
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	9166000
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8817000
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5794000
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-53000
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	828000
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1479000
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6400000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	5932000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	8338000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	7338000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-606000
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.29
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.40
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.35
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.27
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.38
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.33
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20489532
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20622320
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20753789
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20869589
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21579721
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21848359
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21998660
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22167358
CY2016Q1	us-gaap	Revenues Revenues	42989000
CY2016Q2	us-gaap	Revenues Revenues	54567000
CY2016Q1	us-gaap	Gross Profit GrossProfit	21279000
CY2016Q2	us-gaap	Gross Profit GrossProfit	26215000
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	3400000
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8042000
CY2016Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19972395
CY2016Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20840367
CY2016Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20997429
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	879000
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	550000
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	2521000
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	7492000
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.13
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.38
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.12
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.36
CY2016Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19827669

Files In Submission

Name	View Source	Status
0001564590-18-003518-index-headers.html	Edgar Link	pending
0001564590-18-003518-index.html	Edgar Link	pending
0001564590-18-003518.txt	Edgar Link	pending
0001564590-18-003518-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g2018022719505286723102.jpg	Edgar Link	pending
g2018022719510164323103.jpg	Edgar Link	pending
ingn-10k_20171231.htm	Edgar Link	pending
ingn-20171231.xml	Edgar Link	completed
ingn-20171231.xsd	Edgar Link	pending
ingn-20171231_cal.xml	Edgar Link	unprocessable
ingn-20171231_def.xml	Edgar Link	unprocessable
ingn-20171231_lab.xml	Edgar Link	unprocessable
ingn-20171231_pre.xml	Edgar Link	unprocessable
ingn-ex231_290.htm	Edgar Link	pending
ingn-ex311_12.htm	Edgar Link	pending
ingn-ex312_11.htm	Edgar Link	pending
ingn-ex321_6.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INGN
Inogen Inc Stock $ingn

2017 Form 10-K Financial Statement

#000156459018003518 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN Inogen Inc Stock $ingn

2017 Form 10-K Financial Statement

#000156459018003518 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INGN
Inogen Inc Stock $ingn